Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Intraocular Lymphoma 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Carcinoma, Neuroendocrine 2Blast Crisis 2Thymoma 1Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Ovarian Neoplasms 1

Interventions

Topotecan 10Etoposide 7Specimen Handling 6berzosertib 5Cisplatin 5Biopsy 5sargramostim 4Platinum 4Magnetic Resonance Spectroscopy 4Irinotecan 4Carboplatin 4trioctyl phosphine oxide 3X-Rays 3Paclitaxel 3Nivolumab 31,2-diaminocyclohexaneplatinum II citrate 3veliparib 2romidepsin 2olaparib 2cabozantinib 2aldesleukin 2Tomography, X-Ray Computed 2Temozolomide 2Sunitinib 2PM 01183 2Electrocardiography 2Depsipeptides 2Decitabine 2Cyclophosphamide 2Budesonide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Small Cell Lung Carcinoma × belinostat × Clear all
NCT00926640 2018-10-19

A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
28 enrolled
EndocrineThoracic

Carcinoma, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡